Addex Therapeutics, Ltd. - Pangali EV/EBITDA ADXN

Addex Therapeutics (ADXN) is implementing software robots to analyze clinical trial datasets and is testing automated screening stations. The business relies on IT platforms that model nervous system modulators, eliminating routine labor for personnel. The strategy focuses on developing mild drugs to treat dystonia and Parkinson's disease. This price chart shows EV/EBITDA at 0.00.
Rincian analitis perusahaan addextherapeutics.com (ADXN)

To build a defensive portfolio, fundamental screening requires analyzing business value relative to operating profit. The EV/EBITDA ratio for Addex Therapeutics (ADXN) correlates the total enterprise value, including debt, with earnings before interest, taxes, depreciation, and amortization, thereby determining the asset payback period. For Addex Therapeutics (ADXN), the trend of this indicator reflects market expectations regarding the success of Parkinson's disease drugs and the effectiveness of patent protection.